Management Changes

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") focused on developing innovative treatments for mental health and neurological conditions, advises of the appointment of Mr Simon Kemp to General Manager of Clinical Operations and the resignation of Chief Financial Officer, Mr Joseph Ohayon.

Mr Kemp will assume the newly created role of General Manager of Clinical Services. Mr Kemp brings extensive experience in founding, scaling, and growing clinical services. Notably, he co-founded Sleep Studies Australia, where he expanded services nationally and grew annual revenue to \$3.5 million. In addition, Mr Kemp has successfully negotiated Service Level Agreements with private hospitals and private health insurers as well as nurtured extensive clinician referral networks. His expertise in establishing and expanding clinical services, coupled with strong networks in both the private and public healthcare sectors and strong financial acumen, is expected to support Emyria's growth in clinical services and to enhance patient care.

The Company also announces the resignation of Chief Financial Officer, Mr Joseph Ohayon. The Board of Directors of Emyria would like to acknowledge Mr Ohayon's contribution to the Company since joining in 2022 and wish him every success going forward.

Contingency arrangements have been put in place to cover the role and duties vacated by Mr Ohayon.

This release has been approved by the Managing Director of Emyria.

For further information, investment opportunities, or more about our approach to mental health treatment, please contact:

Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com

Media Contact Haley Chartres +61 (0) 423 139 163 haley@hck.digital Corporate Advisor Sufian Ahmad +61 (0) 412 316 162 info@62capital.com.au

emyria emyria.com

Emyria Limited is focused on developing and delivering new treatments for mental health and select neurological conditions through through an integrated model of direct clinical services and drug development:



Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD $^{\rm 1}$




Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.



Emyria's Pipeline: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases as well as high potency dose forms of Ultra-Pure CBD seeking registration for a range of mental health and neuroscience indications.

EMYRIA'S INTERACTIVE INVESTOR HUB





CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.